SCHEMBL26164994

SCHEMBL26164994

CC(C)(C)OC(=O)Nc1sc(Br)cc1C(=O)NCC=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.37
HDAC1 Q13547 7/20 0.36
HDAC6 Q9UBN7 6/20 0.36
HDAC3 O15379 5/20 0.36
HDAC10 Q969S8 4/20 0.36
RXFP1 Q9HBX9 1/20 0.35
HDAC2 Q92769 4/20 0.34
HDAC8 Q9BY41 4/20 0.34
CHEK1 O14757 1/20 0.34
HDAC4 P56524 2/20 0.34
HDAC7 Q8WUI4 2/20 0.34
HDAC11 Q96DB2 2/20 0.34
HDAC9 Q9UKV0 2/20 0.34
HDAC5 Q9UQL6 2/20 0.34
ACHE P22303 1/20 0.34
BACE1 P56817 1/20 0.34
FPR3 P25089 1/20 0.32
FPR2 P25090 1/20 0.32
ALOX15 P16050 1/20 0.32
CYP17A1 P05093 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26164987 0.81 ACACB (0.36) LCKHDAC1HDAC6HDAC3HDAC10
SCHEMBL25204257 0.80 CHEK1 (0.38) CHEK1ALOX15
SCHEMBL3495317 0.80 NPC1 (0.41) LCKRXFP1
SCHEMBL3500334 0.79 HSD17B10 (0.44) LCKRXFP1
SCHEMBL1681287 0.79 IKBKB (0.39) LCKHDAC6CHEK1
SCHEMBL25782417 0.79 ESRRG (0.47)
SCHEMBL22774379 0.79 CA1 (0.44) LCK
SCHEMBL21930986 0.78 ALDH1A1 (0.47)
SCHEMBL27713034 0.72 LCK (0.37) LCKHDAC1HDAC3RXFP1HDAC2
SCHEMBL14679555 0.70 TRPA1 (0.40) LCKHDAC1HDAC6HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 WO disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 LCK 1493/4885HDAC1 1527/4885HDAC6 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.